Some researchers are questioning a claim made by the authors of a recent study that it is feasible to use drug treatment to reduce the risk that patients with prehypertension will progress to hypertension.
In that study, the Trial of Preventing Hypertension (TROPHY), participants were randomly assigned to receive an angiotensin II receptor blocker, candesartan (AstraZeneca LP, London, England), or placebo for 2 years. All patients were then given placebo and followed up for an additional 2 years (Julius S et al. N Engl J Med. 2006;354:1685-1697).
Mitka M. Drug Therapy for Prehypertension Questioned. JAMA. 2006;296(23):2787-2788. doi:10.1001/jama.296.23.2787